Skip to main content
. 2020 Jun 24;11(1):156–180. doi: 10.1016/j.apsb.2020.06.003

Figure 6.

Figure 6

Identification of candidate compound 19d. (A) The anti-proliferation activity of 19d, RVX-208 and Olaparib towards MDA-MB-468 and MCF-7 cells. (B) The inhibitory activity of 19d, RVX-208 and Olaparib for BRD4 and PARP1 were detected by activity assay in diverse concentrations. (C) MDA-MB-468 cells treated with 19d and RVX-208 for 24 h at 2 μmol/L, the expression of BRD4 and c-Myc were detected by Western blot. β-Actin was used as a loading control. (D) MDA-MB-468 cells treated with 19d and Olaparib for 24 h at 2 μmol/L, the expression of PARP and PAR were detected by Western blot. β-Actin was used as a loading control. (E) MDA-MB-468 cells treated with DMSO, 1, 3.3 and 10 μmol/L of 19d for 24 h, the expression levels of BRD4, c-Myc, PARP and PAR were detected by Western blot. β-Actin was used as a loading control. ∗∗∗P < 0.001 compared with control group. Data are present as means ± SD, n = 3.